secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001650664-24-000078
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reni-cel RUBY trial: 18 SCD patients VOE-free; EdiTHAL: 7 TDT patients transfusion-free
--------------------------------------------------------------------------------

- 18 SCD patients free of vaso-occlusive events post-reni-cel (follow-up 2.4-22.8 months); mean total Hb >14 g/dL, HbF >40%.
- 7 TDT patients transfusion-free for 4.1-12.8 months; mean total Hb 12.1 g/dL at month 6, HbF 10.9 g/dL.
- No serious adverse events related to reni-cel in either trial; safety profile consistent with myeloablative conditioning.
- Median neutrophil engraftment 23 days (SCD and TDT); platelet engraftment 24 days (SCD), 38 days (TDT).
- Further clinical update from both trials expected by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000078/0001650664-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000078/edit-20240614.htm
  HTML page:      https://secwatch.observer/filing/0001650664-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer